#United States #New York #Securities Fraud #Pomerantz Law #Grace Therapeutics

Pomerantz Law Firm Takes Action for Grace Therapeutics Investors

Pomerantz LLP, a renowned law firm in the field of class action litigation, has announced an investigation focused on the investors of Grace Therapeutics, Inc. (NASDAQ: GRCE). This investigation arises in the light of potential securities fraud and other illicit business operations that may involve the company and certain individuals associated with it.

On April 23, 2026, Grace Therapeutics made headlines when it disclosed that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) concerning its New Drug Application (NDA) for GTx-104, a treatment aimed at patients with aSAH (aneurysmal subarachnoid hemorrhage). This response from the FDA was critical, highlighting various issues in the Chemistry, Manufacturing, and Controls (CMC) section of the application. The FDA's critique included concerns related to data about product packaging, toxicology risk assessments, and manufacturing deficiencies at the company's contract manufacturing organization.

As a result of this negative news, Grace Therapeutics faced a significant decline in its stock value, which plummeted by $1.96, representing a staggering loss of 45.48%, closing at $2.35 per share on the day of the announcement. This rapid decline has raised alarms among investors, prompting them to consider legal actions to recover potential losses incurred due to the alleged misconduct of the company.

Pomerantz LLP encourages all potentially affected investors to reach out for further information on the possibility of joining a class action. The firm has an established history of successfully representing victims of securities fraud and corporate misconduct, boasting numerous multimillion-dollar recoveries for class members over its 85 years of operation.

Danielle Peyton, an attorney at Pomerantz LLP, is the point of contact for investors seeking to explore their rights and remedies. Interested parties can contact her at [email protected] or call 646-581-9980, extension 7980. Pomerantz has built a reputation as a leading firm focused on safeguarding the interests of investors, advocating for ethical practices in corporate governance.

This investigation comes at a critical time as investors are increasingly vigilant about safeguarding their investments in a volatile market. Companies must uphold high standards of transparency and accountability, and the actions taken by Pomerantz LLP underscore its commitment to protecting investors from potential fraud.

Pomerantz LLP, with offices in major cities such as New York, Los Angeles, and Paris, is celebrated for its pioneering work in securities class actions, led by the legacy of its founder, Abraham L. Pomerantz. As the firm continues its rigorous investigation, stakeholders in the financial community and current investors of Grace Therapeutics remain watchful for further developments that may impact the company's trajectory.

For those keeping an ear to the ground in the biopharmaceutical sector, the fallout from Grace Therapeutics' recent troubles may signal a shift in investor sentiment and regulatory scrutiny within the industry. Keeping informed and involved is essential for all stakeholders as this case unfolds.